#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2912	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2301	371.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1782	1782	T	385	T,C,A	349,3,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2912	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2301	371.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1516	1516	C	425	C	365	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4858	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3975	366.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1876	1876	A	449	A,G	383,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4858	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3975	366.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2510	2510	C	445	C,A	373,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4858	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3975	366.2	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3136	3136	T	421	T,C	361,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4858	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3975	366.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2584	2584	A	456	A,T	374,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	510	folP	855	855	100.0	folP.l6.c4.ctg.1	2055	74.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1224	1226	AGC	130;130;131	A,C;G;C	106,1;109;111	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1228	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3700	99.0	1	SNP	p	S91F	1	.	.	271	273	TTC	711	713	TTC	114;113;111	T;T;C	100;96;94	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1228	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3700	99.0	1	SNP	p	D95G	1	.	.	283	285	GGC	723	725	GGC	110;110;111	G;G;C	95;96;94	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1228	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3700	99.0	1	SNP	p	G95N	0	.	.	283	285	GGC	723	725	GGC	110;110;111	G;G;C	95;96;94	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	474	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1779	80.0	1	SNP	p	G45D	0	.	.	133	135	GGC	707	709	GGC	114;112;112	G;G;C	95;91;93	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	300	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	1203	73.9	0	.	n	.	0	A197.	DEL	197	197	A	679	679	A	117	A	107	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1074	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3362	95.9	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1669	1671	GTC	109;109;109	G;T;C	91;93;90	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1074	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3362	95.9	1	SNP	p	D86N	0	.	.	256	258	GAC	775	777	GAC	128;127;127	G;A,G,T;C	107;106,1,1;112	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1074	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3362	95.9	1	SNP	p	S87R	1	.	.	259	261	CGT	778	780	CGT	127;126;126	C;G;T	110;111;109	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1074	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3362	95.9	1	SNP	p	R87I	0	.	.	259	261	CGT	778	780	CGT	127;126;126	C;G;T	110;111;109	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1074	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3362	95.9	1	SNP	p	R87W	0	.	.	259	261	CGT	778	780	CGT	127;126;126	C;G;T	110;111;109	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1074	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3362	95.9	1	SNP	p	S88P	0	.	.	262	264	TCC	781	783	TCC	128;129;130	T;C,T;C	108;114,1;110	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	866	parE	1986	1986	99.95	parE.l6.c4.ctg.1	2951	87.4	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1530	1532	TGC	104;106;107	T;G;C,T	86;91;89,1	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	866	parE	1986	1986	99.95	parE.l6.c4.ctg.1	2951	87.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1740	1742	GGC	111;111;111	G;G,A;C	94;92,1;95	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	814	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2818	86.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1500	1502	GCA	111;112;112	G,A;C;A,T	91,2;94;95,1	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	814	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2818	86.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1503	1505	ATC	111;112;113	A;T;C,T	97;92;98,1	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	814	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2818	86.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1515	1517	GTG	110;109;108	G;T;G	90;85;89	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	814	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2818	86.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1515	1517	GTG	110;109;108	G;T;G	90;85;89	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	814	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2818	86.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2019	2021	ACC	100;100;99	A;C;C	82;79;83	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	814	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2818	86.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2073	2075	GCG	96;95;96	G;C;G	74;73;77	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	814	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2818	86.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2073	2075	GCG	96;95;96	G;C;G	74;73;77	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	814	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2818	86.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2196	2198	GGC	98;98;99	G;G,C;C	78;82,1;82	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	814	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2818	86.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2205	2207	GGC	97;97;97	G;G;C,A,G	77;79;80,1,1	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	814	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2818	86.6	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2223	2225	TCG	96;95;95	T;C,A;G	76;80,1;82	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1148	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3378	101.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1819	1821	CCG	121;121;122	C,T;C,T,A;G	97,1;99,1,1;102	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	624	porA	1146	1146	99.56	porA.l6.c4.ctg.1	2230	83.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	863	863	C	100	C	91	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	76	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1508	14.9	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1234	1236	AAT	12;12;12	A;A;T	10;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	76	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1508	14.9	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1237	1239	AAT	12;12;12	A;A;T	8;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	76	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1508	14.9	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1261	1263	GCA	12;12;12	G;C;A	11;11;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	76	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1508	14.9	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1284	1286	GTA	10;10;10	G;T;A	10;9;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	76	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1508	14.9	0	.	p	.	0	S236N	NONSYN	706	708	AGC	1290	1292	AAC	10;10;10	A;A;C	10;8;9	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	76	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1508	14.9	0	.	p	.	0	.	MULTIPLE	709	711	AAC	1294	1299	TGGCAT	10;10;10;10;10;10	T;G;G;C;A;T	9;10;10;9;10;9	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	76	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1508	14.9	0	.	p	.	0	D238A	NONSYN	712	714	GAT	1300	1302	GCT	10;9;9	G;C;T	9;8;9	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	76	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1508	14.9	0	.	p	.	0	V258L	NONSYN	772	774	GTA	1360	1362	TTA	6;6;6	T;T;A	6;6;6	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	76	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1508	14.9	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	1405	1407	CAT	7;7;7	C;A;T	6;6;6	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	76	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1508	14.9	0	.	p	.	0	D274S	NONSYN	820	822	GAT	1408	1410	AGT	7;7;7	A;G;T	6;6;6	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	76	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1508	14.9	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1417	1419	TAC	6;6;6	T;A;C	5;5;5	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	530	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	2114	75.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	601	603	GAA	98;100;100	G;A;A	88;88;88	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	530	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	2114	75.0	0	.	p	.	0	N134D	NONSYN	400	402	AAT	889	891	GAT	128;126;125	G;A;T,C	107;107;104,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	530	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	2114	75.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1012	1014	TCA	125;125;125	T;C;A	103;101;105	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	530	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	2114	75.0	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1141	1143	GTC	124;126;126	G;T;C	106;105;106	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	530	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	2114	75.0	0	.	p	.	0	R258H	NONSYN	772	774	CGT	1261	1263	CAT	118;119;119	C;A;T	98;100;100	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	530	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	2114	75.0	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1471	1473	GCA	101;102;101	G;C;A	90;88;87	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	530	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	2114	75.0	1	SNP	p	G120K	1	.	.	358	360	AAG	847	849	AAG	120;120;120	A,C;A,G;G	102,1;99,1;101	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	530	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	2114	75.0	1	SNP	p	D121N	0	.	.	361	363	GAC	850	852	GAC	120;121;121	G;A;C	99;101;103	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	530	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	2114	75.0	1	SNP	p	A121D	1	.	.	361	363	GAC	850	852	GAC	120;121;121	G;A;C	99;101;103	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2048	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5364	114.5	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2274	2276	AAT	121;121;122	A;A;T	112;114;116	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	274	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1425	57.7	1	SNP	p	V57M	1	.	.	169	171	ATG	708	710	ATG	101;100;100	A;T;G,A	86;86;85,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
